According to Lukang Pharmaceutical's announcement, the company received the “Drug Registration Certificate” for briprazole tablets issued by the State Drug Administration. The specifications are 2 mg, 1 mg, and 0.25 mg. Briprazole is a second-generation atypical antipsychotic and has been widely recommended by authoritative guidelines at home and abroad. Currently, 24 domestic companies have been approved for generic drugs according to the new registration classification. Domestic sales for the first quarter of 2025 and 2026 were 4.62 million yuan and 5.96 million yuan respectively. The company invested about 7.12 million yuan in R&D. The drug was approved to enrich the company's formulation pipeline and enhance competitiveness, but sales are uncertain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.